Want to see IL:CANF full AI Analyst Report?
Can Fite Bio (CANF) AI Stock Analysis
Can Fite Bio
(TASE:CANF)
The overall score is low because the company exhibits a highly fragile financial profile with minimal revenue, large recurring losses, and substantial cash burn funded largely through equity. Weak technicals, including a sustained downtrend and deeply oversold momentum indicators, further pressure the rating. Valuation remains speculative given negative earnings and no dividend, offering limited support until there is clearer progress toward profitability.
Can Fite Bio (CANF) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 11.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 19.29K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -0.47
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Israel
- Employees
- 5
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Can Fite Bio Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver...
How the Company Makes Money
As a clinical-stage biotech, Can-Fite has not consistently generated recurring product revenue from marketed drugs. The company’s primary sources of cash have typically been (1) external financing (e.g., public offerings or other capital raises) and...
Can Fite Bio Financial Statement Overview
Summary
Financials are very weak: minimal revenue (~$0.4M) against large and persistent TTM net losses (~$9.6M), deeply negative and deteriorating margins, shrinking equity, and heavy negative operating and free cash flow near $9.5M, partially offset by low leverage and a high gross margin typical of early-stage biotech.
Income Statement
23NegativeBalance Sheet
41NeutralCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 405.00K | 438.40K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 405.00K | 412.42K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -9.73M | -10.74M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -9.55M | -10.64M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 8.05M | 9.52M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.04M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 49.00K | 71.01K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.20M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -9.51M | -9.69M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -9.51M | -9.69M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -4.00M | -2,164 | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.04M | 10.44M | 6.71M | 9.14M | 0 | 20.46M |
Can Fite Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 256.30 is below the 20-day moving average (MA) of 297.06, below the 50-day MA of 366.01, and below the 200-day MA of 510.84, indicating a bearish trend. The MACD of -25.62 indicates Negative momentum. The RSI at 25.70 is Positive, neither overbought nor oversold. The STOCH value of 19.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.
Can Fite Bio Risk Analysis
Can Fite Bio disclosed 68 risk factors in its most recent earnings report. Can Fite Bio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskCan Fite Bio Peers Comparison
Overall Rating
IL:BLRX41Neutral- IL:CANF40.2Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:CANF | Can-Fite BioPharma Ltd. | 256.30 | 255.30 | 25530.00% | |
| IL:HDST.M | HBL- Hadasit Bio-Holdings Ltd. | 60.00 | 16.10 | 36.67% | |
| IL:XTLB | XTL Biopharmaceuticals Ltd. | 1.40 | -2.20 | -61.11% | |
| IL:BLRX | BioLineRX Ltd. | 1.00 | -0.90 | -47.37% | |
| IL:GEFR | Cannomed Medical Cannabis Industries Ltd. | 75.80 | -5.80 | -7.11% | |
| IL:MTLF | Matricelf Ltd. | 247.20 | -188.80 | -43.30% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 14, 2026